All In Biotech

Investigational drug · Phase 3

HRS-5965

Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Primary IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

6

3 still active

All registered trials

14

Any phase or sponsor naming "HRS-5965"

First trial start

2023

Dec 19, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "HRS-5965", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Primary IgA Nephropathy
  • Paroxysmal Nocturnal Hemoglobinuria

Approved drugs for the same conditions: Paroxysmal nocturnal hemoglobinuria · IgA nephropathy · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "HRS-5965" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Primary IgA Nephropathy

  • TelitaciceptRC18, RC18-LPhase 38 trials

    RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease

  • NTQ5082Phase 34 trials

    Nanjing Chia-tai Tianqing Pharmaceutical · Paroxysmal Nocturnal Hemoglobinuria, Primary IgA Nephropathy

  • SefaxersenRO7434656Phase 31 trial

    Roche (Genentech) · Primary IgA Nephropathy

  • SHR-2173Phase 25 trials

    Guangdong Hengrui Pharmaceutical Co., Ltd · Generalized Myasthenia Gravis, Active Lupus Nephritis, Primary IgA Nephropathy

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.